6.2.2. metastatic disease (stage iia/b). 6.2.2.1. stage iia/b seminoma patients enlarged retroperitoneal lymph nodes < 2 cm greatest diameter normal markers may observed six eight weeks repeat-staging imaging may non-metastatic average 10% cases. treatment initiated metastatic disease unequivocal, based biopsy, increasing nodal size/number, subsequent marker rise . special case patients undergo primary rplnd within trial institutional study (see details). historically, radiotherapy primary treatment stage ii a/b seminoma, showing relapse rates 9-24% . recommended radiation doses stage iia iib 30 gy 36 gy, respectively. doses, five-year relapse-free survival rates stand 92% stage iia 90% iib . reduced dose 27 gy stage iia associated higher relapse rate . chemotherapy standard option stage iia/b seminoma, relapse rates 0-8% stage iia disease 8-14% stage iib disease, excellent overall survival 99% . standard regimen stage ii seminoma bep x 3 (see appendix 4.1.2) epx4 concerns use bleomycin . randomised studies comparing radiotherapy chemotherapy. meta-analysis thirteen high-quality studies, comparing efficacy toxicity radiotherapy chemotherapy showed appeared similarly effective stage iia/iib patients although non-significant trend towards greater efficacy chemotherapy (hr: 2.17) stage iib seminoma . acute toxicity almost exclusively reported following chemotherapy, long-term toxicity frequent following radiotherapy, mainly comprising bowel toxicity secondary cancers, generally irradiated field . several series shown increased risk developing second solid cancer 1.8-2.0-fold radiotherapy . long term toxicities chemotherapy including second cancers also concern . 6.2.2.1.1. retroperitoneal lymph node dissection several institutional series single-arm phase ii studies explored primary rplnd without adjuvant chemotherapy alternative chemotherapy men low volume cs ii a/b [158-162]. differences surgical technique/template, extent use adjuvant chemotherapy, patient selection, length follow-up make direct comparisons surgical series chemotherapy difficult. reports, patients low-volume cs ii a/b seminoma two-year recurrence rates 5-30%, immature os outcomes owing short follow-up. relapse almost always cured standard chemotherapy. longer follow-up ideally, comparative prospective studies required ensure recommended safe stand-alone treatment option equivalent chemotherapy alone. primary rplnd men low volume cs ii seminoma performed surgeons extensive experience specialised tc centres. ideally, procedure take place within prospective cohort clinical trial order maintain surgical quality monitor long-term oncological outcomes. 6.2.2.1.2. de-escalating approaches several trials attempted de-escalate chemotherapy rt, aiming maintaining traditional excellent oncologic result, minimising treatment burden toxicity. approach evaluated phase ii randomised trial, assessing chemotherapy de-escalation patients guided metabolic response fdg-pet/ct two initial cycles etoposide, cisplatin (ep) chemotherapy . patients complete metabolic response ep x 2 received de-escalated treatment one subsequent cycle carboplatin auc7, whilst patients residual metabolic activity completed initial schedule ep x 4. study showed comparable three-year pfs rate 90% 91% ep carboplatin groups respectively, two-year os 100% groups. despite apparently maintained oncological efficacy, larger studies longer follow-up needed. reasons owing absence consensus criteria fdg-petc/ct interpretation, making treatment decisions based solely fdg-pet/ct responses currently recommended routine use . another de-escalation option emerged, involving one cycle carboplatin followed involved-node (small-volume) radiotherapy (30 gy 15 sessions stage iia 36 gy 18 sessions stage iib). approach shown three-year progression-free survival rate 93.7% single-arm phase ii trial, narrowly missing target primary endpoint 95% three-year pfs . currently approaches lack level evidence needed routine use recommendation. summary evidenceleat stage de-escalation strategies, including rplnd remain evaluation considered high volume specialised centres within prospective cohort clinical trial.3 figure 2: treatment options patients seminoma clinical stage iia b* *when enlarged retroperitoneal lymph nodes < 2 cm normal markers, treatment initiated unless metastatic disease unequivocal based biopsy, increasing nodal size/number, subsequent marker rise.bep = cisplatin, etoposide, bleomycin; ep = etoposide, cisplatin. 6.2.2.2. stage ii a/b non-seminoma (nsgct) 6.2.2.2.1. serum tumour marker negative patients normal markers equivocal lymph nodes (< 2 cm) may considered initial surveillance early re-evaluation six weeks. lesion progresses fails resolve regarded treated cs ii. cs iia nsgct disease normal normalised tumour markers, nerve sparing rplnd performed experienced surgeon specialised centre recommended initial treatment. patients may staged ps 20% cases require treatment. patients post-pubertal teratoma alone avoid unnecessary chemotherapy surgery alone curative. oncological outcomes rplnd cs ii nsgct evaluated sr . included studies majority retrospective included patients differing substantially histopathology, size number retroperitoneal lymph nodes resected, surgical templates, use adjuvant chemotherapy. men marker negative cs ii nsgct, ps ii confirmed 80%. without adjuvant chemotherapy 12-40% recurred compared 0-4% received adjuvant chemotherapy. findings align large single centre reports outcomes following rplnd alone ps ii nsgct active disease . studies reported five-year relapse less 30%, majority occurring outside retroperitoneum requiring systemic chemotherapy according risk group. adjuvant chemotherapy may discussed patient reduce risk relapse setting. key issues include risk factors relapse (as positive lymph node-ratio), risk overtreatment 70% cases need rigorous follow-up. adjuvant chemotherapy chosen, standard treatment bep ep maximum two cycles . recent single institution real world study including 61 cs iia/b < 3cm nsgct (out 66 gct) active disease, showed 77% two-year progression-free survival without adjuvant chemotherapy stage iia/b < 3 cm, greatest benefit achieved stage iia marker negative cases . figure 3: flowchart nonseminoma cs iia mk- diagnosis/staging* patients good prognostic group (bep x3 pe x4).tm â€“ tumour markers* marker negative pd > iib rplnd may considered radiological features teratoma** good prognostic group (bep x3 ep x4) - see appendix 4https://uroweb.org/guidelines/testicular-cancer/publications-appendices.***in case ps ii a/b patient followed-up receive adjuvant chemotherapy (maximum 2 cycles). 6.2.2.2.2. serum tumour marker positive patients elevated tumor markers radiological stage iia/b diagnosis relapse treated chemotherapy outlined tables 6 7 section 6.2.3.1 based igcccg risk group. patients good prognosis bepx3 appropriate ep x 4 concerns use bleomycin. primary rplnd cs iia/b disease elevated markers recommended outside specific study referral centre .